Prevention of chemotherapy-induced alopecia using an effective scalp cooling system

被引:78
作者
Katsimbri, P [1 ]
Bamias, A [1 ]
Pavlidis, N [1 ]
机构
[1] Univ Hosp, Dept Med Oncol, Ioannina 45110, Greece
关键词
alopecia; taxanes; anthracyclines; etoposide; scalp cooling;
D O I
10.1016/S0959-8049(00)00012-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Alopecia is a distressing side-effect of cancer treatment. Taxanes (TX). anthracyclines (ANR) and etoposide (ET) have been consistently associated with significant alopecia. We studied an effective scalp cooling system, the Penguin Cold Cap system(TM), for the prevention of chemotherapy-induced alopecia in 70 patients receiving chemotherapy, including one of the following major alopecia-causing agents: Group A, TX-based regimes (without ANR); Group B. TX + ANR: Group C, ANR-based regimes (without TX): Group D, ET-based regimes. Protection from hair loss was achieved by maintaining scalp temperatures below 15 degrees C before, during and after chemotherapy by frequent changing of the caps. Assessment was carried out using a grading system From 0 to 4. Grades 0-2 were considered as satisfactory hair protection, whilst Grades 3-4 were considered failures. 57 patients were evaluable for assessment. An overall 81% protection was achieved. In groups C and D 11 of 12 patients (92%) had no alopecia, whilst 30 of 34 patients (88%) treated with taxanes had adequate hair protection. In Group B, 4 of 11 patients (36%) had adequate hair protection. The system was well tolerated and is a very effective method for protection from hair loss caused by TX, ANR and ET. Our results are comparable with and, in most cases, better than those reported in other studies using various alopecia preventive methods. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:766 / 771
页数:6
相关论文
共 34 条
[1]   ADRIAMYCIN - NEW ANTICANCER DRUG WITH SIGNIFICANT CLINICAL ACTIVITY [J].
BLUM, RH ;
CARTER, SK .
ANNALS OF INTERNAL MEDICINE, 1974, 80 (02) :249-259
[2]  
Bonfante V, 1992, Semin Oncol, V19, P38
[3]  
BULOW J, 1985, SCAND J CLIN LAB INV, V43, P505
[4]   ADRIAMYCIN - REVIEW [J].
CARTER, SK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1975, 55 (06) :1265-1274
[5]  
Catimel Gilles, 1997, Seminars in Oncology, V24, P8
[6]   DOCETAXEL IS A MAJOR CYTOTOXIC DRUG FOR THE TREATMENT OF ADVANCED BREAST-CANCER - A PHASE-II TRIAL OF THE CLINICAL SCREENING COOPERATIVE GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER [J].
CHEVALLIER, B ;
FUMOLEAU, P ;
KERBRAT, P ;
DIERAS, V ;
ROCHE, H ;
KRAKOWSKI, I ;
AZLI, N ;
BAYSSAS, M ;
LENTZ, MA ;
VANGLABBEKE, M .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) :314-322
[7]  
Cline B W, 1984, Cancer Nurs, V7, P221
[8]   PREVENTION OF DOXORUBICIN-INDUCED HAIR LOSS WITH SCALP HYPOTHERMIA [J].
DEAN, JC ;
SALMON, SE ;
GRIFFITH, KS .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (26) :1427-1429
[9]  
DEVITA VT, 1997, PHARM CANC CHEMOTHER, P375
[10]  
Dombernowsky P, 1996, SEMIN ONCOL, V23, P13